Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Arcutis Biotherapeutics Inc (NASDAQ: ARQT) closed at $14.86 in the last session, up 9.51% from day before closing price of $13.57. In other words, the price has increased by $9.51 from its previous closing price. On the day, 3.44 million shares were traded. ARQT stock price reached its highest trading level at $14.93 during the session, while it also had its lowest trading level at $13.45.
Ratios:
We take a closer look at ARQT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.38 and its Current Ratio is at 2.46. In the meantime, Its Debt-to-Equity ratio is 1.33 whereas as Long-Term Debt/Eq ratio is at 0.69.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on August 28, 2024, initiated with a Buy rating and assigned the stock a target price of $15.
On January 03, 2024, Mizuho Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $4 to $8.
Mizuho Downgraded its Buy to Neutral on October 26, 2023, whereas the target price for the stock was revised from $57 to $4.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 30 ’24 when Edwards Larry Todd bought 1,093 shares for $7.11 per share. The transaction valued at 7,767 led to the insider holds 137,728 shares of the business.
Matsuda Masaru bought 1,657 shares of ARQT for $11,775 on Nov 30 ’24. The insider now owns 187,030 shares after completing the transaction at $7.11 per share. On May 31 ’24, another insider, Matsuda Masaru, who serves as the insider of the company, bought 4,000 shares for $1.69 each. As a result, the insider paid 6,768 and bolstered with 185,373 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 1739288704 and an Enterprise Value of 1616899584. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.54 while its Price-to-Book (P/B) ratio in mrq is 11.10. Its current Enterprise Value per Revenue stands at 11.657 whereas that against EBITDA is -9.012.
Stock Price History:
Over the past 52 weeks, ARQT has reached a high of $13.60, while it has fallen to a 52-week low of $2.28. The 50-Day Moving Average of the stock is 42.44%, while the 200-Day Moving Average is calculated to be 51.86%.
Shares Statistics:
According to the various share statistics, ARQT traded on average about 2.04M shares per day over the past 3-months and 1801870 shares per day over the past 10 days. A total of 117.00M shares are outstanding, with a floating share count of 102.95M. Insiders hold about 12.04% of the company’s shares, while institutions hold 103.02% stake in the company. Shares short for ARQT as of 1732838400 were 23527848 with a Short Ratio of 11.52, compared to 1730332800 on 27755696. Therefore, it implies a Short% of Shares Outstanding of 23527848 and a Short% of Float of 24.870001.
